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ttp://dx.doi.org/10.1016/j.ajpath.2013.02.028Benign prostate hyperplasia (BPH) is a major cause of lower urinary tract symptoms, with an increased
volume of transitional zone and associated with increased stromal cells. It is known that androgen/
androgen receptor (AR) signaling plays a key role in development of BPH, and that blockade of this
signaling decreases BPH volume and can relieve lower urinary tract symptoms, but the mechanisms of
androgen/AR signaling in BPH development remain unclear, and the effectiveness of current drugs for
treating BPH is still limited. The detailed mechanisms of androgen/AR signaling need to be clariﬁed,
and new therapies are needed for better treatment of BPH patients. This review focuses on roles of AR in
epithelial and stromal cells in BPH development. In epithelial cells, AR may contribute to BPH devel-
opment via epithelial cellestromal cell interaction with alterations of epithelialemesenchymal tran-
sition, leading to proliferation of stromal cells. Data from several mouse models with selective knockout
of AR in stromal smooth-muscle cells and/or ﬁbroblasts indicate that the AR in stromal cells can also
promote BPH development. In prostatic inﬂammation, AR roles in inﬁltrating macrophages and
epithelial and stromal cells have been linked to BPH development, which has led to discovery of new
therapeutic targets. For example, targeting AR with the novel AR degradation enhancer, ASC-J9 offers
a potential therapeutic approach against BPH development. (Am J Pathol 2013, 182: 1942e1949;
http://dx.doi.org/10.1016/j.ajpath.2013.02.028)Supported by NIH grant CA156700, the George H. Whipple Professor-
ship Endowment, the Taiwan Department of Health Clinical Trial, and
Research Center of Excellence grant DOH99-TD-B-111-004 (China
Medical University, Taichung, Taiwan).
Disclosures: ASC-J9 was patented by the University of Rochester, the
University of North Carolina, and AndroScience Corporation, and then was
licensed to AndroScience. Both the University of Rochester and C.C. own
equity in and receive royalties from AndroScience Corporation.Benign prostatic hyperplasia (BPH) is the most common
male benign proliferative disease, and approximately 8
million patients are estimated to visit physicians with the
diagnosis of primary or secondary BPH.1 The incidence of
gross enlargement of the prostate gland has been reported as
40% in 70-year-old men, and microscopic foci of the prostate
gland are present in up to 80% of these men.2 BPH patients
often have lower urinary tract symptoms, and need to be
treated with surgery or medication. Although transurethral
resection of the prostate is the most common surgical treat-
ment for BPH worldwide, the procedure can lead to
complications (eg, bleeding, urethral stricture, incontinence)
and may have limitations for people of advanced age.3e5
Although a-blockers are frequently prescribed for treatment
of BPH and have a quick onset of action, within 3 to 5 days,6
these drugs alone fail to shrink BPH volume and are
often insufﬁcient to eliminate symptoms.7 In contrast, 5-astigative Pathology.
.reductase inhibitors (5-ARIs), which suppress testosterone
conversion into dihydrotestosterone (DHT), have greater
efﬁcacy in reducing BPH volume, and clinical data indicate
that the combination of 5-ARIs with a-blockers leads to the
best symptomatic response to date.8,9
The above clinical data suggest that androgen/androgen
receptor (AR) signaling plays key roles in development of
BPH and that targeting androgen/AR signaling could be
a major therapeutic approach for BPH. Nevertheless, the
AR Roles in BPH Developmentdetailed mechanisms of androgen/AR signaling, and espe-
cially the pathogenic roles of AR in BPH,10 are still unclear.
In this review, we focus on the roles of AR in promoting
prostate stromal cell growth11 and prostate epithelial cell
growth with increased epithelialemesenchymal transition
(EMT).12 We also discuss how AR regulates development
of BPH through the inﬂammatory environment with mac-
rophage inﬁltration, and address potential new therapeutic
approaches, such as targeting AR with the newly identiﬁed
AR degradation enhancer ASC-J9 and/or targeting speciﬁc
inﬂammatory cytokines downstream of AR.
Clinical Evidence of Androgen/AR Roles in
Development of BPH
Basic Evidence for Androgen/AR Roles Supporting
Clinical Effects
The hormone dependency of development of BPH is well
documented, and androgen concentration or AR activity in
BPH patients has been a subject of study since 1895.13 One
study in the 1980s found little difference in AR expression in
prostate tissues isolated from either BPH patients or unaf-
fected control subjects.14 However, the serum concentration
of testosterone and DHT may change with age, with reduced
serum testosterone in healthy old men, relative to that in
healthy younger men. In contrast, DHT levels are elevated,
and serum DHT in BPH patients is signiﬁcantly higher than
that in unaffected men at a similar age.15,16 Similar conclu-
sions were also obtained recently in a large cross-sectional
study that included 505 men aged 40 to 79 years (mean,
58 years); higher serum DHT levels and DHT/testosterone
ratios were associated with larger prostate volume and higher
prevalence of BPH.17
Tang et al18 found no difference in AR expression between
the peripheral zone (PZ) and the transitional zone (TZ) in
BPH. In other studies, although nucleic AR expression was
detected in both epithelial and stromal cells of hyperplastic
nodules, higher nuclear AR expression was detected in
prostate epithelial cells than in stromal cells.19,20 Others
found higher 5-a reductase activity in stromal cells than in
epithelial cells, with AR distributed evenly between epithe-
lial and stromal cells.21,22 Importantly, the primitive BPH
nodules found in the periurethral area of the TZ had higher
concentrations of androgens and higher nuclear AR expres-
sion than those in other prostate regions. These ﬁndings
suggest that androgen/AR signaling may play important roles
in promoting the proliferation of epithelial and stromal cells
in the periurethral area of the TZ, thus leading to develop-
ment of BPH with urinary obstruction (Figure 1).23
Clinical Effects of Antiandrogens and 5-ARIs on BPH
Castrated BPH patients showed a marked decrease of pros-
tatic volume after 2 to 3 months, and this volume reduc-
tion correlated well with a relief of lower urinary tractThe American Journal of Pathology - ajp.amjpathol.orgsymptoms.24,25 A double-blind, randomized trial for BPH
patients with the antiandrogen ﬂutamide (750 mg/day for
6 months) showed signiﬁcantly decreased prostate volume by
35%, compared with controls, within 6 months.26 However,
these androgen-deprivation therapies with surgical or med-
ical castration or with antiandrogens are no longer used as
a standard treatment because of adverse reactions27,28 and
have been replaced by the 5-ARIs, which have better efﬁcacy
in suppressing development of BPH. A study of BPH patients
treated for 1 year with ﬁnasteride, a 5-ARI for 5-a reductase
type 2, showed a signiﬁcant decrease in the size of the peri-
urethral area, as well as total prostate gland size, suggesting
that suppression of testosterone conversion into DHT could
lead to a signiﬁcant decrease in the size of the prostate.29 The
efﬁcacy and safety proﬁles of ﬁnasteride in BPH patients
over a 12-month period also showed a 74% reduction in
serum DHT levels, a 21% reduction in prostate volume,
and a signiﬁcant improvement in urinary obstructive
symptoms.30,31 However, ﬁnasteride treatment led to a 55%
decrease of DHT in epithelial cells of the TZ, with little effect
on stromal cells,32 even though 5-a reductase type 2 is
expressed in both stromal and epithelial cells in the prostate.
In contrast, another 5-ARI, dutasteride, inhibiting both type 2
and type 1 of 5-a reductases (the latter expressed predomi-
nantly in epithelial cells33), showed a greater decrease in
DHT (98.4  1.2%) than did ﬁnasteride (70.8  18.3%).34
Taken together, these clinical studies suggest that androgen/
AR may contribute to the increase of prostate volume, and
5-ARIs with suppression of testosterone conversion into DHT
are effective medicines for reducing BPH size.
Limitations of Current 5-ARIs Targeting Testosterone
Conversion into DHT for Treatment of BPH
Although 5-ARIs have been shown to reduce the volume of
BPH, these may have some limitations. The Combination of
Avodart and Tamsulosin (CombAT) study, with 4844 BPH
patients, showed that combined therapy with both dutasteride
and the a-blocker tamsulosin was signiﬁcantly superior to
either monotherapy in reducing the relative risk of BPH
progression and symptoms.35 Later analysis, however, found
that combined therapy was better than dutasteride mono-
therapy in men with prostate volumes of30 to<58 mL, but
not in men with a prostate volume of <30 or 58 mL.36 The
beneﬁt of combination therapy is thus greatest only in patients
with larger BPH volumes, and a-blockers alone may be
sufﬁcient to alleviate lower urinary tract symptoms in patients
with smaller BPH volumes; however, transurethral resection
of the prostate may be needed for patients with the largest
BPH volumes (approximately 60 mL).6 Importantly, 5-ARIs
have been reported to produce signiﬁcant adverse sexual
reactions, including decreased libido, erectile dysfunction, or
ejaculation problems.37e42 In addition, 5-ARIs may not be
able to suppress completely the intraprostatic DHT in BPH
patients, and the remaining DHT may still be able to trans-
activate AR and lead to development of BPH.1943
Figure 1 Schematic of prostate structure. Most cases of prostate cancer occur in the peripheral zone (PZ), but BPH is caused by enlargement of the transitional
zone (TZ), especially in the periurethral area. The urethra penetrates the periurethral area, sandwiched between left and right adenoma and ﬂattened in BPH.
Izumi et alAR Roles in Promoting Prostate Epithelial Cell
Growth with Enhanced EMT in Development of BPH
Epithelial AR Inﬂuences Cell Growth
Bello et al,43 using the human prostate epithelial cell line
RWPE-1, found that addition of the synthetic androgen
mibolerone increased AR expression level and enhanced cell
growth, and Silva et al44 found that DHT can promote human
primary prostate epithelial cell growth. These in vitro cell-line
data suggest that androgen/AR signaling may play positive
roles in promoting prostate epithelial cell proliferation.
Wuet al45 generated conditional knockoutARmice that lack
ARonly in prostate epithelial cells (pes-ARKO) and found that
the pes-ARKO mice developed larger but less differentiated
prostate with increased cell death, compared with wild-type
littermates. Further analyses of each individual cell type
within the epithelium in pes-ARKO mice revealed that loss of
epithelialAR increased the proportionofCK5þ basal epithelial
cells but decreased the proportion of CK8þ luminal epithelial
cells, suggesting that luminal epithelial AR may play survival
roles and that basal epithelial ARmay play suppressor roles in
maintaining homeostasis of prostate epithelial cells.45 It would
be interesting to learn whether AR in epithelial cells of human
BPH has roles similar to those in the normal prostate.
Epithelial Cells Contribute to Development of BPH via
Epithelial CelleStromal Cell Interaction
Clinical studies showing better efﬁcacy of dutasteride than
ﬁnasteride in suppressing BPH33,34 suggest that prostate1944epithelial cells may play positive roles in promoting devel-
opment of BPH. In two studies from the 1990s, epithelial cell
content was signiﬁcantly greater in the TZ than in the PZ,46
and epithelial cells were only 9.0% of BPH cells.47
However, epithelial cells may still play important roles in
enhancing stromal cell growth via epithelial cellestromal cell
interaction. In coculture of primary human BPH stromal
ﬁbroblasts and epithelial cells, cell growth of cocultured cells
was signiﬁcantly increased, compared to separate culture,48
suggesting that epithelial cells may have a supportive role
in the growth of stromal cells in development of BPH. On the
other hand, stromal androgen/AR signaling may be able to
enhance the expression and/or release of growth factors that
act on epithelial cells.49,50 Thus, prostate epithelial and
stromal cells may each support proliferation of the other cell
type through growth factors in a paracrine manner.Epithelial Cells Contribute to Increased Stromal Cell
Population via EMT and So Contribute to Development
of BPH
EMT is a physiological process in which epithelial cells
acquire the motile characteristics of mesenchymal (stromal)
cells.51 EMT is characterized by decrease of epithelial
markers (eg, E-cadherin) and increase of mesenchymal
and transcriptional factors (eg, N-cadherin, vimentin, and
Snail).52 EMT is associated mainly with cancer progression,
including migration, invasion, and metastasis. Cancer cells
undergoing EMT may acquire invasive properties, entering
the surrounding stromal cells and creating a favorableajp.amjpathol.org - The American Journal of Pathology
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Interestingly, Alonso-Magdalena et al12 found that EMT
may also contribute to development of BPH. Although they
found little evidence of proliferation in clinical human BPH
stromal cells, they found that 0.7% of basal cells and 0.4%
of luminal cells were positive for the proliferation markers
Ki-67 and PCNA in the epithelium of some ducts.12
Importantly, they found that regions of the ductal epithe-
lium had lost their polarization and expressed little E-cad-
herin.12 Others reported that Snail2/Slug is the important
transcriptional factor for TGF-b1einduced EMT of prostate
epithelial cells in BPH.54 These results suggest that EMT in
epithelial cells may also promote development of BPH
(Figure 2).
AR Promotes Development of BPH by Inﬂuencing
Inﬁltrating Immune Cell Migration toward Prostate
Epithelial Cells
Inﬂammation with inﬁltrating macrophages inﬂuences
epithelial cells and may contribute to development of BPH. A
study investigating the association between immune inﬂam-
mation and AR expression in human BPH specimens from
prostatectomy showed that the total prostate volume was
signiﬁcantly higher in specimens with inﬁltrated inﬂam-
matory cells including B or T lymphocytes than in those
without inﬁltrated inﬂammatory cells, suggesting that the
immune inﬂammatory process may also contribute to de-
velopment of BPH.55 A recent study by Lu et al56 also showed
higher expression of the human macrophage marker CD68 in
human BPH specimens, further conﬁrming that inﬁltrated
immune cells may be able to contribute to development of
BPH.
Using coculture of human BPH-1 epithelial cells with
human monocyte/macrophage THP-1 cells, Lu et al56 found
that BPH-1 cells have the capacity to recruit more THP-1
cells. They found that recruited THP-1 cells subsequentlyFigure 2 Schematic of EMT and proliferation in development of BPH.
Epithelial cells (both basal and luminal) undergo EMT, changing their shape
over time to a more spindle-like form (arrows and circles), and proliferate.
The American Journal of Pathology - ajp.amjpathol.orgenhanced BPH-1 cell growth in a three-dimensional culture
system, with increase of EMT in BPH-1 cells, and they
demonstrated that increased TGF-b2 expression in BPH-1
cells and the addition of TGF-b2 neutralizing antibody
suppressed THP-1 macrophages-mediated cell growth and
EMT in BPH-1 cells. Importantly, they found that addition
of AR in BPH-1 cells induced EMT gene expression in
BPH-1 cells and promoted THP-1 macrophage migration
during coculture with THP-1 cells. Addition of the AR
degradation enhancer ASC-J9 also suppressed THP-1
macrophage-mediated cell growth in stably transfected AR
BPH-1 cells.56 Similar data were also obtained when human
BPH-1/THP-1 cells were replaced with mouse epithelial
mPrE cells and mouse macrophage RAW264.7 cells in their
coculture system (Figure 3).56
Taken together, these results demonstrate that epithelial
AR may be able to enhance epithelial cell growth and EMT
induction by inﬂuencing recruitment of inﬁltrating immune
cells, which could then enhance development of BPH.
AR Roles in Prostate Stromal Cell Growth That
Promote Development of BPH
Stromal AR Contributes to Development of BPH
It is well known that prostate cancer occurs predominantly in
the PZ, whereas BPH typically develops in the TZ.57 A study
in the 1990s reported that BPH is comprised of 88.4%
stromal cells and 9.0% epithelial cells,47 and it is therefore
reasonable to think that stromal cells may play a major role in
development of BPH. Jiang et al57 found differences between
stromal cells in the TZ and those in the PZ with regard to AR
expression, DHT response, and cytokine expressions, and
they demonstrated that stromal cells in the PZ, but not the TZ,
are more supportive for prostate cancer epithelial cell growth;
however, little is known about whether stromal cells in the
TZ also contribute to development of BPH.57 In other studies,
DHT concentration and IGF-II activity were highest in the
periurethral area of the TZ in BPH,58 and basic ﬁbroblast
growth factor (FGF) expression in stromal cells, but not in
epithelial cells, was reduced in BPH patients after ﬁnasteride
treatment.59 These results indicate that stromal cells in the TZ
may play an important role in development of BPH via
modulation of androgen/AR signaling and expression of
growth factors and cytokines.
Yu et al60 established the stromal smooth-muscle selec-
tive AR knockout (SM-ARKO) mouse model and found
decreased epithelial cell proliferation, with little change of
apoptosis and differentiation. They also found decreased
IGF-I expression in the prostates of SM-ARKO mice and
primary PS-1 stromal cells with AR knockdown, suggesting
that AR in stromal smooth-muscle cells may also contribute
to development of BPH via regulation of IGF-I signaling.
Yu et al61 also established the stromal ﬁbroblast selective
AR knockout (FSP-ARKO) mouse model, and found that
loss of AR in the stromal ﬁbroblasts decreased proliferation1945
Figure 3 AR of epithelial cells attracts macrophages and interaction between epithelial cells, and macrophage inﬁltration increases secretion of TGF-b2
from epithelial cells. TGF-b2 promotes EMT of epithelial cells and ﬁnally forms spheres in three-dimensional culture. AR of stromal cells attracts macrophages
and interaction between stromal cells and inﬁltrated macrophages increases CCL3 secretion from both stromal cells and inﬁltrated macrophages. This
interaction induces the proliferation of stromal cells.
Izumi et alof epithelial cells with increased apoptosis, which may
involve the suppression of IGF-I and FGFs.
Lai et al62 established the double stromal AR knockout
(dARKO) mouse model with selectively deleted AR in both
stromal ﬁbroblasts and smooth-muscle cells, and found that
the size of the anterior prostate lobes was signiﬁcantly
reduced, compared with those from wild-type littermate
controls. Decreased proliferation and increased apoptosis of
the prostate epithelium in the dARKO mouse anterior
prostate was also observed. Lai et al62 further conﬁrmed
these phenotypic changes with newly established immor-
talized prostate stromal cells (PrSC) from wild-type and
dARKO mice. Mechanism dissection studies on the PrSCs
from these mice again suggested that IGF-I may play key
roles in mediating positive roles of stromal AR in normal
prostate growth.
The above in vivo mouse models showing stromal AR can
promote normal prostate growth were recently further
extended to a prolactin transgenic (Pb-PRL tg) mouse BPH
model. Mice with loss of AR in both stromal ﬁbroblasts and
smooth-muscle cells (dARKO/Pb-PRL tg) developed smaller
prostates with a lower proliferative index and exhibited better
urination function and normal bladder volume, compared
with wild-type/Pb-PRL tg mice (Lai et al, unpublished data).
Mechanism dissection suggested that prolactin-induced
hyperplastic prostate growth involved the epithelial-stromal
interaction through epithelial autonomous prolactin/
prolactin receptor action to regulate granulocyte colony-
stimulating factor and granulocyte/macrophage colony1946stimulating factor production in a paracrine manner to
facilitate stromal cell growth by elevating STAT3 activity
(Lai et al, unpublished data). The results indicated that
stromal AR could modulate such epithelialestromal inter-
acting signals, resulting in promotion of hyperplastic prostate
growth (Lai et al, unpublished data). Furthermore, thera-
peutic approaches targeting stromal AR with ASC-J9
reduced prostate size and suppressed stromal cell prolifera-
tion (Lai et al, unpublished data).
Taken together, results from various stromal ARKO
mouse models suggest that stromal ARmay play crucial roles
in promoting stromal cell growth in both normal prostate and
in development of BPH.
Stromal AR Promotes Development of BPH by
Inﬂuencing Inﬁltrating Macrophage Migration toward
Prostate Stromal Cells
The potential inﬂuence of inﬂammatory inﬁltrating cells on
stromal cell growth during development of BPH has also
been addressed.63,64 Wang et al65 found that the number of
inﬁltrated macrophages increased in stroma of human BPH
specimens, and that mouse stromal mPrSC cells had the
capacity to recruit more inﬁltrating macrophage RAW264.7
cells in a coculture system. The consequent increase of
macrophage inﬁltration toward stromal cells could promote
the proliferation of stromal mPrSC cells.65
Mechanism dissection further revealed a remarkable
increase of expression of the cytokine CCL3 in both mPrSCajp.amjpathol.org - The American Journal of Pathology
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system, and addition of neutralizing CCL3 antibody resulted
in a signiﬁcant reduction of the migration of macrophage
RAW264.7 cells toward stromal cells and a signiﬁcant
reduction of macrophage-enhanced stromal mPrSC cell
proliferation during coculture.65
These in vitro coculture data were further conﬁrmed using
an in vivo prolactin-induced BPH mouse model in a study
showing increased macrophage numbers and CCL3 expres-
sion, compared with those from wild-type littermate con-
trols.65 Importantly, targeting stromal AR via deletion of the
stromal ﬁbromuscular AR in the prolactin-induced BPH
model reduced the number of inﬁltrated macrophages and
reduced CCL3 expression in prostate tissues. These ﬁndings
conﬁrm in vitro coculture data and support the key role of
prostate stromal AR in controlling CCL3 expression, which
could affect macrophage inﬁltration and prostate stromal cell
growth during development of BPH.65 Moreover, human
clinical immunohistochemical analysis also revealed higher
expression of CCL3 in human BPH prostates, compared with
normal prostates.65
Taken together, the various ﬁndings described above lead
to the conclusion that stromal AR may promote development
of BPH by enhancing the recruitment of inﬁltrating macro-
phages with increased CCL3 expression, thereby increasing
stromal cell growth (Figure 3).65
Targeting AR with ASC-J9 as a New Therapeutic
Approach to Treatment of BPH
The conclusion that AR in both stromal and epithelial cells
may play key roles in promoting development of BPH
suggests that targeting AR could provide a potential thera-
peutic approach for BPH. Alternatively, targeting AR-
regulated downstream genes (eg, TGFB2 or CCL3) could
provide a potential therapeutic approach. Indeed, Lu et al56
and Wang et al65 reported that treatment with ASC-J9 sup-
pressed epithelial and stromal cell growth, respectively.
Importantly, injection of ASC-J9 into prolactin-induced BPH
mice also led to suppression of development of BPH. Early
studies have demonstrated well the efﬁcacy of ASC-J9 in
treating several AR-related diseases, including prostate can-
cer,66e68 liver cancer,69,70 and bladder cancer,71 as well as
promoting wound healing,72 with little change in serum
testosterone concentration and less toxicity or adverse effects
in sexual function or fertility.66e73 ASC-J9 thus has potential
as a candidate drug targeting AR for treatment of BPH.
Further in vivo or clinical studies of this agent for treatment of
BPH may be expected.Conclusions
Androgen/AR signaling plays key roles in enhancing cell
growth in both stromal and epithelial cells, thus promoting
development of BPH. Although BPH is comprised largelyThe American Journal of Pathology - ajp.amjpathol.orgof stromal cells, epithelial cells may still play an important
role in development of BPH via epithelial cellestromal cell
interaction or EMT. One such mechanism with positive roles
of AR involves increased recruitment of inﬁltrating macro-
phages, with modulation of some cytokines. Targeting AR
may therefore provide a reasonable therapeutic approach for
treatment of BPH. ASC-J9, which offers improved efﬁcacy
in targeting AR and reduction in number or severity of
adverse effects, has the potential to become a next-generation
therapy for BPH patients.
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